Hypoactive sexual desire disorder
disease diseaseOn this page
Also known as lack or loss of sexual desire
Summary
Hypoactive sexual desire disorder (MONDO:0001821) is a disease and 49 clinical trials. Top therapeutic interventions include testosterone, bremelanotide, and buspirone. A subtype of psychosexual disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 49
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | hypoactive sexual desire disorder |
| Mondo ID | MONDO:0001821 |
| DOID | DOID:13868 |
| ICD-10-CM | F52.0 |
| NCIT | C94337 |
| SNOMED CT | 270903007 |
| UMLS | C0020594 |
| MedGen | 43792 |
| Is cancer (heuristic) | no |
Also known as: lack or loss of sexual desire
Disease family
This is a subtype of psychosexual disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › sexual disorder › psychosexual disorder › hypoactive sexual desire disorder
Related subtypes (4): paraphilic disorder, psychologic vaginismus, psychologic dyspareunia, orgasm disorder
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 49.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 18 |
| Not specified | 14 |
| PHASE2 | 9 |
| PHASE4 | 4 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01208038 | PHASE4 | COMPLETED | Testosterone Patch’s Effects on the Cardiovascular System and Libido |
| NCT02714049 | PHASE4 | TERMINATED | Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy |
| NCT02968342 | PHASE4 | UNKNOWN | Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women |
| NCT04179734 | PHASE4 | COMPLETED | Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder |
| NCT00131495 | PHASE3 | COMPLETED | Study of Transdermal Testosterone Patches in Menopausal Women With Low Libido |
| NCT00140153 | PHASE3 | COMPLETED | Testosterone in Female Hypoactive Sexual Desire Disorder |
| NCT00331123 | PHASE3 | COMPLETED | Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido |
| NCT00331214 | PHASE3 | COMPLETED | Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido |
| NCT00338312 | PHASE3 | COMPLETED | Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido |
| NCT00349791 | PHASE3 | COMPLETED | Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido |
| NCT00384046 | PHASE3 | COMPLETED | Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen |
| NCT00467259 | PHASE3 | COMPLETED | Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women |
| NCT00612742 | PHASE3 | COMPLETED | Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women |
| NCT00613002 | PHASE3 | COMPLETED | Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women |
| NCT00657501 | PHASE3 | COMPLETED | Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women |
| NCT01235754 | PHASE3 | COMPLETED | Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) |
| NCT02333071 | PHASE3 | COMPLETED | 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder |
| NCT02338960 | PHASE3 | COMPLETED | 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder |
| NCT03287232 | PHASE3 | COMPLETED | Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) |
| NCT03463707 | PHASE3 | COMPLETED | BP101 for Adults With Female Sexual Dysfunction |
| NCT03619005 | PHASE3 | WITHDRAWN | Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study |
| NCT04943068 | PHASE3 | COMPLETED | A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal) |
| NCT06082817 | PHASE2 | NOT_YET_RECRUITING | An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD |
| NCT07596212 | PHASE1/PHASE2 | NOT_YET_RECRUITING | BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder |
| NCT00034021 | PHASE2 | COMPLETED | Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction |
| NCT01382719 | PHASE2 | COMPLETED | Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder |
| NCT01432665 | PHASE2 | COMPLETED | Lybrido for Female Sexual Dysfunction |
| NCT01743235 | PHASE2 | COMPLETED | Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems |
| NCT01857596 | PHASE1/PHASE2 | COMPLETED | Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety |
| NCT02101203 | PHASE2 | COMPLETED | Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder |
| NCT02419209 | PHASE2 | COMPLETED | The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause |
| NCT02593396 | PHASE2 | COMPLETED | Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men |
| NCT03080298 | PHASE2 | COMPLETED | Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire |
| NCT01096329 | PHASE1 | TERMINATED | A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa® |
| NCT03102489 | PHASE1 | COMPLETED | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers |
| NCT00281372 | Not specified | COMPLETED | Sexual Dysfunction and Dental Care |
| NCT00551785 | Not specified | TERMINATED | Surveillance Study of Women Taking Intrinsa® |
| NCT00569413 | Not specified | SUSPENDED | A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality |
| NCT00916396 | Not specified | UNKNOWN | Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder |
| NCT01702818 | Not specified | COMPLETED | Stress Hormones, Mood and Women’s Sexual Desire (MODEST) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TESTOSTERONE | 4 | 8 |
| BREMELANOTIDE | 4 | 5 |
| BUSPIRONE | 4 | 3 |
| FLIBANSERIN | 4 | 2 |
| GINKGO | 4 | 1 |
| GONADORELIN ACETATE | 4 | 1 |
| PRASTERONE | 4 | 1 |
| TESTOSTERONE UNDECANOATE | 4 | 1 |
| CHEMBL4746472 | 0 | 8 |
| CHEMBL2370644 | 0 | 1 |
| CHEMBL31399 | 0 | 1 |